Clinical Trial: Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209410) titled 'Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma' on Oct. 01.

Brief Summary: To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Glaucoma

Intervention: DRUG: Brimonidine Tartrate Ophthalmic 0.025%

Lumify is an approved eye drop to minimize ocular hyperemia.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Insight Eyecare Specialtie...